TY - JOUR
T1 - Growth Differentiation Factor (GDF)-15 and Cardiometabolic Outcomes among Older Adults
T2 - The Atherosclerosis Risk in Communities Study
AU - Echouffo-Tcheugui, Justin B.
AU - Daya, Natalie
AU - Matsushita, Kunihiro
AU - Wang, Dan
AU - Ndumele, Chiadi E.
AU - Al Rifai, Mahmoud
AU - Hoogeveen, Ron C.
AU - Ballantyne, Christie M.
AU - Selvin, Elizabeth
N1 - Funding Information:
The Atherosclerosis Risk in Communities Study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I). J.B. Echouffo-Tcheugui was supported by NIH/NHLBI grant K23 HL153774. E. Selvin was supported by NIH/NHLBI grant K24 HL152440, and NIH/NIDDK grant R01DK089174. E. Selvin and C.M. Ballantyne were supported by R01-HL134320. Roche supplied reagents for the measurement of GDF-15, NT-proBNP and hs TnT. C.E. Ndumele is supported by NIH grant R01HL146907. R.C. Hoogeveen has received grant support from Denka Seiken outside the scope of the current research study.
Publisher Copyright:
© 2021 American Association for Clinical Chemistry 2021. All rights reserved.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - Introduction: Laboratory studies suggest an involvement of growth differentiation factor 15 (GDF-15) in metabolic dysregulation. However, the utility of GDF-15 for assessing risk of cardiometabolic outcomes has not been rigorously examined among older adults. Methods: We conducted a cross-sectional analysis of older adults who attended visit 6 (2016-2017) of the Atherosclerosis Risk in Communities (ARIC) Study. We used multivariable logistic regression to quantify cross-sectional associations of GDF-15 (in quartiles) with prevalent diabetes, obesity, atherosclerotic cardiovascular disease (ASCVD), subclinical myocardial stress/injury (assessed by NT-proB-type Natriuretic Peptide [NT-proBNP] and high-sensitivity cardiac troponin T [hs-cTnT]), and heart failure (HF). Results: Among 3792 ARIC study participants (mean age 80 years, 59% women, 23% Blacks and 77% Whites, mean GDF-15: 2094.9 pg/mL [SD: 1395.6]), higher GDF-15 concentrations (highest vs. lowest quartile) were positively associated with diabetes (adjusted odds ratio [aOR]:]: 2.48, 95% CI: 1.89, 3.26), ASCVD (aOR: 1.57, 95% CI: 1.16, 2.11), increased hscTnT (aOR: 2.27, 95%CI: 1.54, 3.34), increased NT-proBNP (aOR: 1.98, 95%CI: 1.46, 2.70), and HF (aOR: 3.22, 95%CI: 2.13, 4.85), in models adjusted for demographics and traditional cardiovascular risk factors. Conclusions: In this sample of older US black and whites, increased GDF-15 was positively associated with diabetes, ASCVD, HF, and markers of subclinical myocardial stress or injury. These results illustrate the diverse aspects of the link between GDF-15 and diseases states, and its potential utility as robust biomarker of adverse cardiometabolic outcomes.
AB - Introduction: Laboratory studies suggest an involvement of growth differentiation factor 15 (GDF-15) in metabolic dysregulation. However, the utility of GDF-15 for assessing risk of cardiometabolic outcomes has not been rigorously examined among older adults. Methods: We conducted a cross-sectional analysis of older adults who attended visit 6 (2016-2017) of the Atherosclerosis Risk in Communities (ARIC) Study. We used multivariable logistic regression to quantify cross-sectional associations of GDF-15 (in quartiles) with prevalent diabetes, obesity, atherosclerotic cardiovascular disease (ASCVD), subclinical myocardial stress/injury (assessed by NT-proB-type Natriuretic Peptide [NT-proBNP] and high-sensitivity cardiac troponin T [hs-cTnT]), and heart failure (HF). Results: Among 3792 ARIC study participants (mean age 80 years, 59% women, 23% Blacks and 77% Whites, mean GDF-15: 2094.9 pg/mL [SD: 1395.6]), higher GDF-15 concentrations (highest vs. lowest quartile) were positively associated with diabetes (adjusted odds ratio [aOR]:]: 2.48, 95% CI: 1.89, 3.26), ASCVD (aOR: 1.57, 95% CI: 1.16, 2.11), increased hscTnT (aOR: 2.27, 95%CI: 1.54, 3.34), increased NT-proBNP (aOR: 1.98, 95%CI: 1.46, 2.70), and HF (aOR: 3.22, 95%CI: 2.13, 4.85), in models adjusted for demographics and traditional cardiovascular risk factors. Conclusions: In this sample of older US black and whites, increased GDF-15 was positively associated with diabetes, ASCVD, HF, and markers of subclinical myocardial stress or injury. These results illustrate the diverse aspects of the link between GDF-15 and diseases states, and its potential utility as robust biomarker of adverse cardiometabolic outcomes.
KW - GDF-15
KW - cardiovascular disease
KW - diabetes
KW - metabolism
UR - http://www.scopus.com/inward/record.url?scp=85103683435&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103683435&partnerID=8YFLogxK
U2 - 10.1093/clinchem/hvaa332
DO - 10.1093/clinchem/hvaa332
M3 - Article
C2 - 33582779
AN - SCOPUS:85103683435
SN - 0009-9147
VL - 67
SP - 653
EP - 661
JO - Clinical Chemistry
JF - Clinical Chemistry
IS - 4
ER -